What Researchers Did
Researchers conducted a randomized, crossover trial in five healthy men to determine the single-dose pharmacokinetics of intravenous gentamicin under normobaric oxygen and hyperbaric oxygen conditions.
What They Found
They found no significant difference in gentamicin's pharmacokinetic values between hyperbaric and normobaric oxygen conditions. Key pharmacokinetic values, including beta half-life (112 vs 115 min) and peak concentration (6.52 vs 7.23 mg/L), showed no significant difference, and similarly, volume of distribution (0.201 vs 0.184 L/kg) and clearance (0.0754 vs 0.0676 L/kg/hr) remained unchanged.
What This Means for Canadian Patients
Canadian patients receiving a single dose of gentamicin while undergoing hyperbaric oxygen therapy are unlikely to experience altered drug levels. This suggests that standard gentamicin dosing may be appropriate in this specific scenario, but further research on multiple doses is warranted for drugs with narrow therapeutic indexes.
Canadian Relevance
This study was conducted in a specialized hyperbaric research facility within a United States Air Force medical center and has no direct Canadian connection.
Study Limitations
A key limitation is that the study only evaluated single-dose gentamicin, meaning cumulative effects from multiple hyperbaric oxygen exposures remain unknown.